drugset / Trial / NCT01669941

Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya

NCT01669941

RandomizedParallel-groupOpen-labelPrevention

Summary

Malaria in pregnancy (MiP) due to Plasmodium falciparum infection is a major cause of maternal morbidity and poor birth outcomes. Intermittent preventive treatment in pregnancy (IPTp) with Sulfadoxine pyrimethamine (SP), the administration of SP at predefined intervals in the second and third trimesters of pregnancy irrespective of the presence of malaria parasitemia, is currently recommended for HIV-negative women in all areas with stable moderate to high transmission of malaria. Due to increasing resistance to SP, it is no longer used as a treatment for symptomatic malaria, and the efficacy of IPTp-SP seems to be decreased. This study aims to look at a new drug, Dihydroartemisinin-Piperaquine (DP) for IPTp, as well as to explore the strategy of intermittent screening and treatment in pregnancy (ISTp) with DP. This strategy uses increased screening at time of focused antenatal care (FANC) with treatment of women who screen positive. The hypothesis is that the efficacy of both IPTp-DP and ISTp-DP will be associated with a reduction in malaria infection at delivery among HIV(-) women when compared to IPTp-SP, in an area with decreasing malaria transmission and high levels of SP resistance in Kenya.

Timeline

Start
2012-08
Primary completion
2014-10
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 80 mg Oral
Subject ARTENIMOL Small molecule 120 mg Oral
Subject ARTENIMOL Small molecule 160 mg Oral
Subject piperaquine Small molecule 640 mg Oral
Subject piperaquine Small molecule 960 mg Oral
Subject piperaquine Small molecule 1280 mg Oral
Comparator pyrimethamine Small molecule 75 mg
Comparator sulfadoxine Small molecule 1500 mg